Fingerprint
Dive into the research topics of 'A Fifty-Two–Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A Fifty-Two–Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
Atul Deodhar, Lianne S. Gensler, Jonathan Kay, Walter P. Maksymowych, Nigil Haroon, Robert Landewé, Martin Rudwaleit, Stephen Hall, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Brian Kilgallen, Désirée van der Heijde
Research output: Contribution to journal › Article › peer-review
67
Scopus
citations